Ascendis Pharma, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.1M | 3,260 | 82.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 577 | 10.8% |
| Consulting Fee | $417,251 | 145 | 3.1% |
| Travel and Lodging | $293,413 | 1,100 | 2.2% |
| Food and Beverage | $239,513 | 6,664 | 1.8% |
| Education | $367.36 | 36 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| foresiGHt | $2.5M | 0 | 274 |
| New InsiGHts | $1.7M | 0 | 703 |
| enliGHten | $1.6M | 0 | 510 |
| foresiGHt extension | $1.0M | 0 | 136 |
| PaTH Forward | $863,837 | 0 | 179 |
| ApproaCH | $742,970 | 0 | 54 |
| PaTHway TRIAL | $694,652 | 1 | 107 |
| EAP of Palopegteriparatide in Patients With Hypoparathyroidism | $566,781 | 0 | 1,064 |
| SkybriGHt | $552,858 | 1 | 83 |
| SkyPASS | $540,885 | 1 | 81 |
| PaTHway | $204,267 | 0 | 54 |
| Emerald | $117,310 | 0 | 7 |
| IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 / Alone or in Combination with Pembrolizumab or Standard of Care Chemotherapy in Participants Aged 18 Years or Older with Locally Advanced or Metastatic Solid Tumor Malignancies | $52,838 | 0 | 7 |
| BelieveIT-201 | $34,710 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Courtney Reints, Dnp, DNP | Pediatric Endocrinology | Des Moines, IA | $9,033 | $0 |
| Dr. Dennis Brenner, M.d, M.D | Pediatric Endocrinology | West Orange, NJ | $8,926 | $0 |
| Lisa Orloff, Md, MD | Otolaryngology | Stanford, CA | $8,829 | $0 |
| Dr. Mehmet Burak, M.d, M.D | Endocrinology, Diabetes & Metabolism | Cambridge, MA | $8,427 | $0 |
| Dr. Mushtaq Syed, Md, MD | Endocrinology, Diabetes & Metabolism | Indiana, PA | $8,389 | $0 |
| Suparna Jain, M.d, M.D | Pediatric Endocrinology | Santa Monica, CA | $8,373 | $0 |
| Samer Nakhle, Md, MD | Internal Medicine | Las Vegas, NV | $8,346 | $0 |
| Lance Sloan, Md, MD | Nephrology | Lufkin, TX | $8,138 | $0 |
| Grazyna Piekos-Sobczak, M.d, M.D | Pediatrics | Phoenix, AZ | $8,074 | $0 |
| Mr. Gnanagurdasan Prakasam, Md, MD | Pediatric Endocrinology | Sacramento, CA | $7,993 | $0 |
| Dr. Priyanka Iyer, M.d, M.D | Endocrinology, Diabetes & Metabolism | Houston, TX | $7,360 | $0 |
| Richard Rosenthal | Endocrinology, Diabetes & Metabolism | Birmingham, AL | $7,328 | $0 |
| Dr. Intekhab Ahmed, M.d, M.D | Internal Medicine | Philadelphia, PA | $7,298 | $0 |
| Kanakasabai Narasimhan, Md, MD | Endocrinology, Diabetes & Metabolism | Charlotte, NC | $7,129 | $0 |
| Lee Metchick, Md, MD | Endocrinology, Diabetes & Metabolism | Deland, FL | $7,113 | $0 |
| Minou Tran, M.d, M.D | Endocrinology, Diabetes & Metabolism | Pico Rivera, CA | $6,919 | $0 |
| Abdul Al-Kassab, Md, MD | Endocrinology, Diabetes & Metabolism | Rochester Hills, MI | $6,835 | $0 |
| Wynter Kipgen, M.d, M.D | Endocrinology, Diabetes & Metabolism | Stillwater, OK | $6,780 | $0 |
| Dr. Ricardo Correa Marquez, M.d, M.D | Endocrinology, Diabetes & Metabolism | East Providence, RI | $6,754 | $0 |
| Mr. Tom Connally, Md, MD | Surgery | Norman, OK | $6,531 | $0 |
| Lawrence Silverman, Md, MD | Pediatric Endocrinology | Morristown, NJ | $6,494 | $0 |
| Daniel Flynn, Md, MD | Pediatric Endocrinology | Boise, ID | $6,460 | $0 |
| Dr. Juliana Austin, Md, MD | Pediatrics | Long Beach, CA | $6,210 | $0 |
| Jesus Perez, Md, MD | Endocrinology, Diabetes & Metabolism | Sarasota, FL | $6,202 | $0 |
| Ervin Szoke, Md, MD | Endocrinology, Diabetes & Metabolism | Port St John, FL | $6,182 | $0 |
About Ascendis Pharma, Inc.
Ascendis Pharma, Inc. has made $13.6M in payments to 2,551 healthcare providers, recorded across 11,782 transactions in the CMS Open Payments database. In 2024, the company paid $4.2M. The top product by payment volume is SKYTROFA ($5.8M).
Payments were distributed across 82 medical specialties. The top specialty by payment amount is Pediatric Endocrinology ($996,259 to 291 doctors).
Payment categories include: Food & Beverage ($239,513), Consulting ($417,251), Research ($11.1M), Travel & Lodging ($293,413).
Ascendis Pharma, Inc. is associated with 3 products in the CMS Open Payments database.